AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company, stands at a critical juncture as it navigates the loss of ...

AbbVie executives said they have high hopes for Skyrizi and Rinvoq in the inflammatory bowel disease market after Humira ...

The schizophrenia drug Emraclidine failed to perform in clinical trials but executives say it can still “play a role.” ...

Losing U.S. exclusivity in early 2023, Humira, the top-selling arthritis medication from AbbVie, let biosimilars from Amgen ( ...

Abbvie said on Friday it would record a charge of about $3.5 billion related to its experimental schizophrenia drug, ...

AbbVie's strong financials and potential for cash flow make it a valuable investment, despite risks from patent expirations.

ABBV’s Successful New Drugs — Skyrizi and Rinvoq AbbVie lost patent protection for its blockbuster drug, Humira, in the United States in January 2023 and in the EU in 2018. Humira's sales are ...

Even after a flurry of corporate updates during the first two days of the J.P. Morgan Healthcare Conference, many more ...

The company's immunology portfolio, led by Skyrizi and Rinvoq, continues to thrive despite Humira's patent expiration, ...

AbbVie's $3.5 Billion Blow: Can Bold Bets Revive Its Profit Forecasts?

These characteristics make dividend growth stocks compelling investments in any market environment. The strategy's success ...